Investigational Drug
Telisotuzumab adizutecan
TrialFetch AI Analysis
Show TrialFetch AI Analysis
Overview
Telisotuzumab adizutecan (Temab-A, ABBV-400) is an investigational antibody–drug conjugate being studied in advanced solid tumors. ABT-700 refers to its antibody component, telisotuzumab, rather than to the complete drug. Published human results come primarily from early-phase studies; the response rates below do not establish how it compares with standard treatments. (aacrjournals.org)
Mechanism of action
The telisotuzumab antibody targets the c-Met protein and carries adizutecan, a topoisomerase 1 inhibitor payload intended to kill tumor cells. It should not be confused with telisotuzumab vedotin, which uses a different payload. (aacrjournals.org)
Efficacy
In phase I studies of Temab-A given alone, reported objective response rates were:
- Metastatic colorectal cancer: 15.6% among 122 previously treated patients across dose groups; median response duration was 5.9 months. (pubmed.ncbi.nlm.nih.gov)
- Gastric or gastroesophageal-junction adenocarcinoma: 29% among 42 patients; median response duration was 4.2 months. (pubmed.ncbi.nlm.nih.gov)
- EGFR-mutated nonsquamous non-small-cell lung cancer: 63% among 41 patients in a conference abstract; response-duration data were still immature. (ascopubs.org)
- Platinum-resistant ovarian, primary peritoneal, or fallopian-tube cancer: 37% among 41 patients in a conference abstract; longer-term outcomes were immature. (asco.org)
These figures come from different, small early-phase groups and should not be compared directly across cancer types. (pubmed.ncbi.nlm.nih.gov)
Safety
Gastrointestinal and blood-related toxicities were common. In the colorectal-cancer study, 10% discontinued treatment because of treatment-related adverse events and 3% had treatment-related deaths. In the gastric-cancer group, 88% experienced a grade 3 or higher treatment-emergent adverse event. Anemia was also prominent in the ovarian-cancer abstract: grade 3 or higher treatment-related anemia occurred in 34%. Interstitial lung disease or pneumonitis has been reported and warrants attention as safety data mature. (pubmed.ncbi.nlm.nih.gov)
Further reading
- Phase I colorectal-cancer and dose-escalation study
- Phase I gastric/gastroesophageal-junction study
- EGFR-mutated lung-cancer conference abstract
- Platinum-resistant ovarian-cancer conference abstract
Last updated: Sep 2026
Active trials using Telisotuzumab adizutecan
Found 5 active trials using this drug:
TrialFetch AI summary: Adults with c-Met–overexpressing refractory metastatic colorectal cancer who have not received a c-Met–targeting agent are randomized to telisotuzumab adizutecan plus bevacizumab or trifluridine/tipiracil plus bevacizumab. Telisotuzumab adizutecan is a c-Met–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT07525206
TrialFetch AI summary: Adults with locally advanced or metastatic nonsquamous NSCLC harboring an EGFR exon 19 deletion or L858R mutation and progressing after one third-generation EGFR TKI receive telisotuzumab adizutecan or investigator-chosen standard of care. Telisotuzumab adizutecan is a c-Met–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT07155187
TrialFetch AI summary: Adults with previously untreated, locally advanced unresectable or metastatic EGFR-mutated nonsquamous NSCLC and ECOG 0–1 are randomized to osimertinib alone or osimertinib plus telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational c-Met–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT07005102
TrialFetch AI summary: Adults with measurable metastatic colorectal cancer and ECOG performance status 0–1 are eligible; prior c-Met–targeted therapy or irinotecan or another topoisomerase inhibitor is excluded. The study tests telisotuzumab adizutecan, a c-Met–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor, with FOLFOX/bevacizumab or fluorouracil/leucovorin/panitumumab, compared with regimens without telisotuzumab adizutecan.
ClinicalTrials.gov ID: NCT06820463
TrialFetch AI summary: Adults with advanced or metastatic nonsquamous NSCLC are eligible; the randomized portion requires no prior systemic treatment for advanced disease and no known actionable genomic alterations, while dose escalation permits one prior regimen. Treatment combines telisotuzumab adizutecan, an investigational c-Met–targeted antibody–drug conjugate carrying a topoisomerase I inhibitor, with the investigational PD-1 antibody budigalimab; randomized comparators are budigalimab or pembrolizumab plus platinum/pemetrexed.
ClinicalTrials.gov ID: NCT06772623
